Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215

[PR Newswire] – THOUSAND OAKS, Calif. and DUBLIN, Sept. 23, 2015 /PRNewswire/ — Amgen (AMGN) and Allergan plc. (AGN) today announced a Phase 3 study of biosimilar candidate ABP 215 met its primary and secondary endpoints. The study evaluated the efficacy and safety of ABP 215 compared with Avastin® (bevacizumab) in adult patients with advanced non-squamous non-small cell lung cancer (NSCLC). The primary endpoint, an assessment of objective response rates (ORR), was within the prespecified margin for ABP 215 compared to bevacizumab, showing clinical equivalence.*